← Back to Analyst Consensus 
ACRV Buy
Acrivon Therapeutics, Inc.
Current Price —
Implied Upside —
Analysts 13
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 12, 2026 (16 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Jan 9, 2026 | Piper Sandler | maintain | Overweight → Overweight | $8 | 54% |
| Nov 25, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $19 | 44% |
| Aug 14, 2025 | Oppenheimer | maintain | Outperform → Outperform | $8 | 52% |
| May 16, 2025 | Jones Trading | downgrade | Buy → Hold | $0 | 50% |
| May 15, 2025 | Oppenheimer | maintain | Outperform → Outperform | $9 | 52% |
| Mar 28, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $19 | 44% |
| Mar 28, 2025 | Oppenheimer | maintain | Outperform → Outperform | $10 | 52% |
| Mar 26, 2025 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $0 | 50% |
| Mar 26, 2025 | Citizens Capital Markets | reiterate | Market Outperform → Market Outperform | $17 | 49% |
| Mar 26, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $19 | 44% |
| Jan 31, 2025 | Cantor Fitzgerald | initiate | — → Overweight | $0 | 50% |
| Nov 14, 2024 | BMO Capital | maintain | Outperform → Outperform | $27 | 53% |
| Nov 14, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $22 | 44% |
| Sep 16, 2024 | JMP Securities | reiterate | Market Outperform → Market Outperform | $17 | 53% |
| Sep 16, 2024 | Ladenburg Thalmann | upgrade | Neutral → Buy | $16 | 45% |
| Sep 16, 2024 | BMO Capital | reiterate | Outperform → Outperform | $28 | 53% |
| Sep 16, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $22 | 44% |
| Aug 13, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $22 | 44% |
| May 15, 2024 | BMO Capital | reiterate | Outperform → Outperform | $25 | 53% |
| May 14, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $22 | 44% |
| Apr 29, 2024 | Ladenburg Thalmann | downgrade | Buy → Neutral | $0 | 45% |
| Apr 26, 2024 | BMO Capital | maintain | Outperform → Outperform | $25 | 53% |
| Apr 25, 2024 | JMP Securities | maintain | Market Outperform → Market Outperform | $17 | 53% |
| Apr 25, 2024 | Piper Sandler | maintain | Overweight → Overweight | $30 | 54% |
| Apr 25, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $20 | 44% |
| Apr 5, 2024 | Ladenburg Thalmann | maintain | Buy → Buy | $14 | 45% |
| Apr 1, 2024 | BMO Capital | reiterate | Outperform → Outperform | $18 | 53% |
| Apr 1, 2024 | JMP Securities | reiterate | Market Outperform → Market Outperform | $14 | 53% |
| Mar 28, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $20 | 44% |
| Mar 1, 2024 | JMP Securities | initiate | — → Market Outperform | $14 | 53% |
| Nov 10, 2023 | BMO Capital | maintain | Outperform → Outperform | $24 | 53% |
| Oct 5, 2023 | Maxim Group | initiate | — → Buy | $24 | 42% |
| Sep 6, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $20 | 44% |
| Aug 18, 2023 | JonesTrading | initiate | — → Buy | $26 | 75% |
| Aug 11, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $20 | 44% |
| Jun 2, 2023 | Oppenheimer | initiate | — → Outperform | $25 | 52% |
| May 8, 2023 | BMO Capital | initiate | — → Outperform | $25 | 53% |
| May 2, 2023 | HC Wainwright & Co. | reiterate | — → Buy | $24 | 44% |
| Apr 20, 2023 | HC Wainwright & Co. | initiate | — → Buy | $24 | 44% |
| Dec 12, 2022 | Cowen & Co. | initiate | — → Outperform | $0 | — |
| Dec 12, 2022 | Jefferies | initiate | — → Buy | $17 | 52% |
| Dec 12, 2022 | Piper Sandler | initiate | — → Overweight | $25 | 54% |
Price Target Trend
Apr 25, 2026 Oct 26, 2026
EPS Estimates
0q —
+1y —
+1q —
0y —
Cross-Platform Signals
No cross-platform signals in the last 90 days